Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Current Opinion in Neurology

New insights in the immune treatment of Guillain–Barré syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

EWEveline J.A. WiegersErasmus MCBJBart C. JacobsGhent University Hospital

Discussion

Loading...

Member takes

Overview

Review highlights recent immune treatments and obstacles in guillain–barré syndrome, suggesting new therapeutic avenues.

Key Points

  • New therapies aim to reduce inflammation in patients with guillain–barré syndrome while preventing nerve damage.
  • A GRADE-based guideline published in 2023 emphasizes updated protocols for diagnosing and treating guillain–barré syndrome.
  • Established treatments like intravenous immunoglobulins and plasma exchange remain crucial for managing guillain–barré syndrome symptoms.
  • Novel study designs and observational comparative studies are essential for evaluating treatment effects in guillain–barré syndrome.

Cite This Study

Wiegers et al. (2025) studied this question.

synapsesocial.com/papers/68c1a77a54b1d3bfb60e0c8chttps://doi.org/10.1097/wco.0000000000001408
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial2024 · 23 citations
  2. 2Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses2023 · 418 citations
  3. 3The added value of ordinal analysis in clinical trials: an example in traumatic brain injury2011 · 196 citations
  4. 4Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome2009 · 214 citations
  5. 5Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria2013 · 802 citations